Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981013007> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W1981013007 endingPage "107" @default.
- W1981013007 startingPage "106" @default.
- W1981013007 abstract "Corticosteroids therapy is the mainstay of treatment for GVHD, however, it heavily impacts on post transplant morbidity and new modalities are continually needed. Alemtuzumab a humanized monoclonal antibody to CD52 has been used mainly as GVHD prophylaxis. Only a few patients have been treated with this antibody. From December 2004 to May 2006, we recruited 13 steroid refractory grade II-IV acute GvHD patients in a prospective trial evaluating the efficacy of alemtuzumab (Campath 1H) after exclusion of other severe HST-related complications. Primary endpoints were response to treatment after 14 and 28 days. Secondary endpoints were side effects and incidence of infectious complications. Treatment consisted of Campath 1H 10mg given s.c. on days 1-5. Median age was 33 years old (range:1-59) years, a fludarabine-based reduce intensive conditioning (RIC) regimen was used and the hematopoietic cells were obtained from HLA-identical siblings in 12 cases and one patient received stem cell from umbilical cord blood. All but one received CSA and MTX for GvHD prophylaxis. GvHD was classified as grade II in 5 patients, III in 6 and IV in 2; predominant organ affected was gut in 6 cases, skin in 7, liver in 4 and combination of gut and skin in 4 patients. In 6 of the 13 patients the clinical manifestations of GVHD were noticed after the first 100 days of HSCT. Complete resolution of GvHD, partial response and no response were seen respectively in 23%, 62% and 15%. Six over the 13 patients were able to decrease steroid use. Five patients developed CMV (pp65) reactivation and 3 of them were successfully treated with valganciclovir. All patients maintained complete chimerism during and after alemtuzumab therapy, and after a median follow-up of 5 months (range, 1- 18months), 8 remain alive, 3 without evidence of GVHD. Five patients died, 3 due to GvHD and the others due to infectious complications. This preliminary study suggests that alemtuzumab is a well-tolerated agent and has a beneficial effect in the treatment of refractory GvHD. It is only a pilot study and more studies are needed, but we suggest that this modality could be used early in the management of these patients in order to improve quality of life and reduce the long-term side effects of corticosteroids." @default.
- W1981013007 created "2016-06-24" @default.
- W1981013007 creator A5000360404 @default.
- W1981013007 creator A5002963570 @default.
- W1981013007 creator A5015602718 @default.
- W1981013007 creator A5027053378 @default.
- W1981013007 creator A5070096873 @default.
- W1981013007 creator A5071179664 @default.
- W1981013007 creator A5081793986 @default.
- W1981013007 date "2007-02-01" @default.
- W1981013007 modified "2023-10-18" @default.
- W1981013007 title "294: Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease" @default.
- W1981013007 doi "https://doi.org/10.1016/j.bbmt.2006.12.299" @default.
- W1981013007 hasPublicationYear "2007" @default.
- W1981013007 type Work @default.
- W1981013007 sameAs 1981013007 @default.
- W1981013007 citedByCount "1" @default.
- W1981013007 crossrefType "journal-article" @default.
- W1981013007 hasAuthorship W1981013007A5000360404 @default.
- W1981013007 hasAuthorship W1981013007A5002963570 @default.
- W1981013007 hasAuthorship W1981013007A5015602718 @default.
- W1981013007 hasAuthorship W1981013007A5027053378 @default.
- W1981013007 hasAuthorship W1981013007A5070096873 @default.
- W1981013007 hasAuthorship W1981013007A5071179664 @default.
- W1981013007 hasAuthorship W1981013007A5081793986 @default.
- W1981013007 hasBestOaLocation W19810130071 @default.
- W1981013007 hasConcept C120665830 @default.
- W1981013007 hasConcept C121332964 @default.
- W1981013007 hasConcept C126322002 @default.
- W1981013007 hasConcept C141071460 @default.
- W1981013007 hasConcept C142424586 @default.
- W1981013007 hasConcept C2776694085 @default.
- W1981013007 hasConcept C2776755627 @default.
- W1981013007 hasConcept C2777408962 @default.
- W1981013007 hasConcept C2778384904 @default.
- W1981013007 hasConcept C2779015954 @default.
- W1981013007 hasConcept C2779263901 @default.
- W1981013007 hasConcept C2779972918 @default.
- W1981013007 hasConcept C2781413609 @default.
- W1981013007 hasConcept C2911091166 @default.
- W1981013007 hasConcept C61511704 @default.
- W1981013007 hasConcept C71924100 @default.
- W1981013007 hasConcept C87355193 @default.
- W1981013007 hasConcept C90924648 @default.
- W1981013007 hasConceptScore W1981013007C120665830 @default.
- W1981013007 hasConceptScore W1981013007C121332964 @default.
- W1981013007 hasConceptScore W1981013007C126322002 @default.
- W1981013007 hasConceptScore W1981013007C141071460 @default.
- W1981013007 hasConceptScore W1981013007C142424586 @default.
- W1981013007 hasConceptScore W1981013007C2776694085 @default.
- W1981013007 hasConceptScore W1981013007C2776755627 @default.
- W1981013007 hasConceptScore W1981013007C2777408962 @default.
- W1981013007 hasConceptScore W1981013007C2778384904 @default.
- W1981013007 hasConceptScore W1981013007C2779015954 @default.
- W1981013007 hasConceptScore W1981013007C2779263901 @default.
- W1981013007 hasConceptScore W1981013007C2779972918 @default.
- W1981013007 hasConceptScore W1981013007C2781413609 @default.
- W1981013007 hasConceptScore W1981013007C2911091166 @default.
- W1981013007 hasConceptScore W1981013007C61511704 @default.
- W1981013007 hasConceptScore W1981013007C71924100 @default.
- W1981013007 hasConceptScore W1981013007C87355193 @default.
- W1981013007 hasConceptScore W1981013007C90924648 @default.
- W1981013007 hasIssue "2" @default.
- W1981013007 hasLocation W19810130071 @default.
- W1981013007 hasOpenAccess W1981013007 @default.
- W1981013007 hasPrimaryLocation W19810130071 @default.
- W1981013007 hasRelatedWork W1985674596 @default.
- W1981013007 hasRelatedWork W2007213117 @default.
- W1981013007 hasRelatedWork W2043459751 @default.
- W1981013007 hasRelatedWork W2071890759 @default.
- W1981013007 hasRelatedWork W2076085163 @default.
- W1981013007 hasRelatedWork W2081782066 @default.
- W1981013007 hasRelatedWork W2522221045 @default.
- W1981013007 hasRelatedWork W2550272059 @default.
- W1981013007 hasRelatedWork W4232576625 @default.
- W1981013007 hasRelatedWork W4255153219 @default.
- W1981013007 hasVolume "13" @default.
- W1981013007 isParatext "false" @default.
- W1981013007 isRetracted "false" @default.
- W1981013007 magId "1981013007" @default.
- W1981013007 workType "article" @default.